Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Source: View publication →
In patients with severe, uncontrolled asthma, the anti-TSLP monoclonal antibody tezepelumab significantly reduced the annualized rate of asthma exacerbations compared to placebo, demonstrating efficacy across a broad population regardless of baseline inflammatory biomarkers.
Key Findings
Study Design
Study Limitations
Clinical Significance
The NAVIGATOR trial fundamentally shifted the management of severe asthma by validating the upstream alarmin thymic stromal lymphopoietin (TSLP) as a crucial therapeutic target. By demonstrating a 56% reduction in exacerbations, alongside marked improvements in lung function and symptom control, tezepelumab proved effective in a broad severe asthma population. Crucially, its benefit extended to patients with non-eosinophilic, 'type 2-low' asthma (blood eosinophils <300 cells/µL), a demographic that historically had no viable biologic options and responded poorly to traditional targeted therapies (like anti-IgE or anti-IL-5). This led to tezepelumab's approval as a first-in-class biologic for severe asthma without phenotype or biomarker restrictions.
Historical Context
Prior to the development of tezepelumab, the therapeutic landscape for severe asthma was revolutionized by biologics targeting specific downstream mediators of type 2 (T2) inflammation, such as omalizumab (anti-IgE), mepolizumab and benralizumab (anti-IL-5), and dupilumab (anti-IL-4/IL-13). However, a significant proportion of patients with severe asthma exhibit non-T2 or mixed inflammatory phenotypes, rendering them largely ineligible for or unresponsive to these targeted agents. Tezepelumab was developed to inhibit TSLP, an epithelial cytokine (alarmin) secreted in response to various triggers (allergens, viruses, pollutants) that initiates multiple downstream inflammatory cascades, including both T2 and non-T2 pathways. Following the promising phase 2 PATHWAY study, NAVIGATOR was the definitive phase 3 trial that solidified TSLP blockade as a broadly effective strategy, leading to tezepelumab's FDA approval in December 2021.
Guided Discussion
High-yield insights from every perspective
Tezepelumab targets TSLP (thymic stromal lymphopoietin). How does the position of TSLP in the inflammatory cascade explain why tezepelumab is effective even in patients with low eosinophil counts, unlike anti-IL-5 therapies?
Key Response
TSLP is an epithelial alarmin released at the very top of the cascade in response to airway insults. Because it sits upstream of multiple pathways (both Type 2 and non-Type 2 inflammation), blocking it prevents the activation of various downstream effector cells (eosinophils, neutrophils, mast cells), providing broad efficacy regardless of baseline eosinophil phenotype.
You are evaluating a patient with severe, uncontrolled asthma who has an absolute eosinophil count of 110 cells/mcL and a FeNO of 15 ppb. Why might tezepelumab be chosen over mepolizumab or dupilumab for this specific patient?
Key Response
This patient has a T2-low phenotype (low eosinophils and low FeNO). Current anti-IL-5 (mepolizumab) and anti-IL-4R (dupilumab) biologics are primarily effective in T2-high asthma. The NAVIGATOR trial demonstrated that tezepelumab significantly reduces exacerbations regardless of baseline inflammatory biomarkers, making it a preferred biologic for severe, uncontrolled T2-low asthma.
While the NAVIGATOR trial showed efficacy across all baseline biomarker subgroups, the magnitude of exacerbation reduction still correlated with baseline eosinophil and FeNO levels. How should this nuanced finding influence our phenotyping and biologic selection in a patient who qualifies for both anti-TSLP and anti-IL-4R therapies?
Key Response
Although tezepelumab works in T2-low patients, the relative risk reduction in exacerbations was highest in patients with high baseline eosinophils and FeNO. For a patient qualifying for multiple biologics, the presence of specific co-morbidities (e.g., nasal polyposis favoring dupilumab) and the precise magnitude of biomarkers still matter. Fellows must recognize that broadly effective does not mean equally effective across all phenotypes.
Given tezepelumab's broad efficacy across asthma phenotypes, is there still a clinical justification for routinely measuring traditional biomarkers (IgE, eosinophils, FeNO) in severe asthma, or does this pan-pathway biologic render targeted phenotyping obsolete?
Key Response
While tezepelumab is broadly effective, phenotyping remains critical. Biomarkers help predict the magnitude of response to tezepelumab and guide the use of alternative targeted biologics that might treat specific Type 2 co-morbidities (like atopic dermatitis or chronic rhinosinusitis with nasal polyps) more effectively. Furthermore, step-therapy requirements and cost considerations mandate a tailored approach rather than a universal default to a single biologic.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The NAVIGATOR trial used a hierarchical testing strategy to evaluate the primary endpoint across subgroups stratified by baseline eosinophil counts. What are the methodological advantages and limitations of this statistical approach when trying to definitively prove efficacy in the notoriously difficult-to-treat T2-low subgroup?
Key Response
Hierarchical testing controls the family-wise error rate, ensuring that secondary endpoints or subgroups are only tested formally if the primary population shows significance. The advantage is robust protection against Type I error. The limitation is that if an upper hierarchy test fails, subsequent tests are only exploratory. Furthermore, powering a study for a whole population and then sub-setting into T2-low means the T2-low group might lack sufficient independent power to show a definitive effect size if not carefully pre-calculated, though NAVIGATOR's sample size mitigated this.
The trial compared tezepelumab to placebo as an add-on to standard of care. As an editor reviewing this for publication, why might you criticize the lack of an active comparator arm (e.g., an anti-IL-5 or anti-IL-4R biologic) for the T2-high patient strata, and how does this affect the manuscript's claims of clinical utility?
Key Response
In modern severe asthma trials, demonstrating superiority over placebo is a low bar for patients with T2-high asthma who already have highly effective approved biologics. A rigorous reviewer would flag that without a head-to-head active comparator, clinicians cannot determine if tezepelumab should replace existing therapies in T2-high patients, limiting the pragmatic clinical utility of the findings for a significant portion of the study population.
Based on the NAVIGATOR trial results, how should GINA guidelines update their algorithm for the management of severe asthma (Step 5), specifically regarding the prerequisite biomarker thresholds currently used to approve biologic therapies?
Key Response
Current GINA guidelines heavily rely on phenotypic biomarkers (blood eosinophils and elevated FeNO) to route patients toward Type 2-targeted biologics. The robust evidence from NAVIGATOR supports introducing a new pathway for patients lacking elevated T2 biomarkers (T2-low asthma), formally recommending anti-TSLP (tezepelumab) as a biologic option for severe uncontrolled asthma regardless of T2 biomarker status, thereby filling a major therapeutic gap in previous guideline iterations.
Clinical Landscape
Noteworthy Related Trials
MENSA Trial
Tested
Mepolizumab 75mg IV or 100mg SC every 4 weeks
Population
Patients with severe eosinophilic asthma with frequent exacerbations
Comparator
Placebo
Endpoint
Rate of clinically significant asthma exacerbations
SIROCCO Trial
Tested
Benralizumab 30mg every 4 or 8 weeks
Population
Patients with severe uncontrolled asthma and elevated eosinophils
Comparator
Placebo
Endpoint
Annual exacerbation rate
QUEST Trial
Tested
Dupilumab 200mg or 300mg subcutaneously every 2 weeks
Population
Patients with moderate-to-severe uncontrolled asthma
Comparator
Placebo
Endpoint
Annualized rate of severe asthma exacerbations
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis